GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival In P
In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab)...